Search

MUC1 Dendritic Cell Vaccine

Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. … The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system

IPH 1101

IPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

T-5224

T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

FAV-201

FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

Lanoteplase

R343

R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

Ruplizumab

Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

Mesmulogene ancovacivec

Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen,

Sulprostone

Sulprostone has been used in trials studying Abortion, Induced.

Daporinad

Daporinad has been used in trials studying the treatment of Melanoma, Cutaneous T-cell Lymphoma, and B-cell Chronic Lymphocytic Leukemia.